Brett Haumann, Theravance
March 17, 2021 09:20 AM EDTUpdated March 18, 05:51 AM
People
Bioregnum
Opinion

A de­part­ing CMO pens a sad farewell as he heads back to the UK bio­phar­ma scene

We’re see­ing the C-suites of a whole group of biotech and phar­ma com­pa­nies in flux this week as lead­er­ship groups evolve and top ex­ecs hunt …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times